Severe Hypertriglyceridemia Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Ionis Pharma, 89bio, Inc., Arrowhead Pharma, Hightide Therapeutics, AstraZeneca, Kowa

The Key Severe Hypertriglyceridemia Companies in the market include - Amarin Corporation, Ionis Pharmaceuticals, 89bio, Inc., Arrowhead Pharmaceuticals, Inc., Hightide Therapeutics, AstraZeneca, Kowa Research Institute, Inc., Regeneron Pharmaceuticals, Mochida Pharmaceutical, NeuroBo Pharma, Arisaph Pharma, Acasti Pharma Inc., and others.

DelveInsight's "Severe Hypertriglyceridemia Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Severe Hypertriglyceridemia, historical and forecasted epidemiology as well as the Severe Hypertriglyceridemia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Severe Hypertriglyceridemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Severe Hypertriglyceridemia Market Forecast [https://www.delveinsight.com/sample-request/severe-hypertriglyceridemia-shtg-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Severe Hypertriglyceridemia Market Report:

*
The Severe Hypertriglyceridemia market size was valued approximately ~USD 2,421 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

*
In 2023, the United States held the largest market share for severe hypertriglyceridemia, comprising about 58% of the total market size in the 7MM, in comparison to other key markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

*
In 2023, Germany recorded the largest market size for severe hypertriglyceridemia among European countries, reaching approximately USD 180 million, whereas Spain had the smallest market size at around USD 100 million.

*
In 2023, the market size for severe hypertriglyceridemia in Japan was estimated at approximately USD 324 million, representing 13% of the total market across the 7MM.

*
The anticipated introduction of new therapies, including ARO-APOC3, is expected to impact the overall market size of severe hypertriglyceridemia in the coming years.

*
In 2023, the total number of prevalent cases of Hypertriglyceridemia in the 7MM was 155 million, and this figure is anticipated to increase by 2034.

*
The United States had the highest diagnosed prevalence of Hypertriglyceridemia among the 7MM countries. According to DelveInsight's estimates, it accounts for approximately 44% of the total diagnosed prevalent cases of hypertriglyceridemia in the 7MM.

*
In 2023, the diagnosed prevalent cases of Severe Hypertriglyceridemia (SHTG) in the 7MM were approximately 3,495 thousand, with expectations for an increase during the forecast period.

*
In 2023, Germany reported the highest number of diagnosed prevalent cases of Hypertriglyceridemia among European countries, with approximately 7 million cases, followed by the UK. Conversely, Spain had the lowest prevalence, with around 4 million cases.

*
In 2023, within the 7MM, severe hypertriglyceridemia cases were classified by etiology. The diagnosed prevalent cases of primary and secondary severe hypertriglyceridemia were approximately 1,500 thousand and 1,980 thousand, respectively.

*
In 2023, the EU4 and the UK reported approximately 1,388 thousand diagnosed prevalent cases of severe hypertriglyceridemia. Among these, Germany accounted for about 364 thousand cases, representing the highest number of diagnosed prevalent cases of severe hypertriglyceridemia in Europe.

*
In 2023, Japan represented 16% of the total diagnosed prevalent cases of severe hypertriglyceridemia in the 7MM, with around 562 thousand cases.

*
Key Severe Hypertriglyceridemia Companies: Amarin Corporation, Ionis Pharmaceuticals, 89bio, Inc., Arrowhead Pharmaceuticals, Inc., Hightide Therapeutics, AstraZeneca, Kowa Research Institute, Inc., Regeneron Pharmaceuticals, Mochida Pharmaceutical, NeuroBo Pharma, Arisaph Pharma, Acasti Pharma Inc., and others

*
Key Severe Hypertriglyceridemia Therapies: VASCEPA/VAZKEPA, Plozasiran (ARO-APOC3), Olezarsen, Pegozafermin (BIO89-100), ARO-APOC3, HTD1801, omefas, K-877, evinacumab, Ethyl Icosapentate, Gemcabene, ARI-3037MO, CaPre, Epanova, and others

*
The Severe Hypertriglyceridemia epidemiology based on gender analyzed that the severityspecific data reveal the highest number of cases were observed in moderate level of HTG

*
The Severe Hypertriglyceridemia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Severe Hypertriglyceridemia pipeline products will significantly revolutionize the Severe Hypertriglyceridemia market dynamics.

Severe Hypertriglyceridemia Overview

Primary illnesses and secondary disorders are the two basic categories into which severe hypertriglyceridemia falls. Genetic illnesses fall under the category of main disorders, with secondary causes and other underlying conditions frequently contributing to the latter.

Get a Free sample for the Severe Hypertriglyceridemia Market Report:

https://www.delveinsight.com/report-store/severe-hypertriglyceridemia-shtg-market [https://www.delveinsight.com/report-store/severe-hypertriglyceridemia-shtg-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Severe Hypertriglyceridemia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Severe Hypertriglyceridemia Epidemiology Segmentation:

The Severe Hypertriglyceridemia market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Severe Hypertriglyceridemia

*
Prevalent Cases of Severe Hypertriglyceridemia by severity

*
Gender-specific Prevalence of Severe Hypertriglyceridemia

*
Diagnosed Cases of Episodic and Chronic Severe Hypertriglyceridemia

Download the report to understand which factors are driving Severe Hypertriglyceridemia epidemiology trends @ Severe Hypertriglyceridemia Epidemiology Forecast [https://www.delveinsight.com/sample-request/severe-hypertriglyceridemia-shtg-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Severe Hypertriglyceridemia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Severe Hypertriglyceridemia market or expected to get launched during the study period. The analysis covers Severe Hypertriglyceridemia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Severe Hypertriglyceridemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Severe Hypertriglyceridemia Therapies and Key Companies

*
VASCEPA/VAZKEPA: Amarin Corporation

*
Plozasiran (ARO-APOC3): Arrowhead Pharmaceuticals, Inc.

*
Olezarsen: Ionis Pharmaceuticals

*
Pegozafermin (BIO89-100): 89bio, Inc.

*
ARO-APOC3: Arrowhead Pharmaceuticals, Inc.

*
HTD1801: HightideTherapeutics

*
omefas: AstraZeneca

*
K-877: Kowa Research Institute, Inc.

*
evinacumab: Regeneron Pharmaceuticals

*
Ethyl Icosapentate: Mochida Pharmaceutical

*
Gemcabene: NeuroBo Pharma

*
ARI-3037MO: Arisaph Pharma

*
CaPre: Acasti Pharma Inc.

*
Epanova: AstraZeneca

Discover more about therapies set to grab major Severe Hypertriglyceridemia market share @ Severe Hypertriglyceridemia Treatment Market [https://www.delveinsight.com/sample-request/severe-hypertriglyceridemia-shtg-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Severe Hypertriglyceridemia Market Strengths

*
The increasing prevalent population and increasing episodes of primary and secondary causes worldwide are likely to cause a surge in treatment options. Consequently, the market will witness a boost in the upcoming year

Severe Hypertriglyceridemia Market Opportunities

*
Medications with better safety and effectiveness, which provide an optimum cure, are the current unmet need of the SHTG disease market.

Scope of the Severe Hypertriglyceridemia Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Severe Hypertriglyceridemia Companies: Amarin Corporation, Ionis Pharmaceuticals, 89bio, Inc., Arrowhead Pharmaceuticals, Inc., Hightide Therapeutics, AstraZeneca, Kowa Research Institute, Inc., Regeneron Pharmaceuticals, Mochida Pharmaceutical, NeuroBo Pharma, Arisaph Pharma, Acasti Pharma Inc., and others

*
Key Severe Hypertriglyceridemia Therapies: VASCEPA/VAZKEPA, Plozasiran (ARO-APOC3), Olezarsen, Pegozafermin (BIO89-100), ARO-APOC3, HTD1801, omefas, K-877, evinacumab, Ethyl Icosapentate, Gemcabene, ARI-3037MO, CaPre, Epanova, and others

*
Severe Hypertriglyceridemia Therapeutic Assessment: Severe Hypertriglyceridemia current marketed and Severe Hypertriglyceridemia emerging therapies

*
Severe Hypertriglyceridemia Market Dynamics: Severe Hypertriglyceridemia market drivers and Severe Hypertriglyceridemia market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Severe Hypertriglyceridemia Unmet Needs, KOL's views, Analyst's views, Severe Hypertriglyceridemia Market Access and Reimbursement

To know more about Severe Hypertriglyceridemia companies working in the treatment market, visit @ Severe Hypertriglyceridemia Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/severe-hypertriglyceridemia-shtg-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Severe Hypertriglyceridemia Market Report Introduction

2. Executive Summary for Severe Hypertriglyceridemia

3. SWOT analysis of Severe Hypertriglyceridemia

4. Severe Hypertriglyceridemia Patient Share (%) Overview at a Glance

5. Severe Hypertriglyceridemia Market Overview at a Glance

6. Severe Hypertriglyceridemia Disease Background and Overview

7. Severe Hypertriglyceridemia Epidemiology and Patient Population

8. Country-Specific Patient Population of Severe Hypertriglyceridemia

9. Severe Hypertriglyceridemia Current Treatment and Medical Practices

10. Severe Hypertriglyceridemia Unmet Needs

11. Severe Hypertriglyceridemia Emerging Therapies

12. Severe Hypertriglyceridemia Market Outlook

13. Country-Wise Severe Hypertriglyceridemia Market Analysis (2020-2034)

14. Severe Hypertriglyceridemia Market Access and Reimbursement of Therapies

15. Severe Hypertriglyceridemia Market Drivers

16. Severe Hypertriglyceridemia Market Barriers

17. Severe Hypertriglyceridemia Appendix

18. Severe Hypertriglyceridemia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=severe-hypertriglyceridemia-market-growth-to-accelerate-in-forecast-period-20242034-delveinsight-analyzes-ionis-pharma-89bio-inc-arrowhead-pharma-hightide-therapeutics-astrazeneca-kowa]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.